#PhRMA14: Collaborating with Patients to Advance R&D

#PhRMA14: Collaborating with Patients to Advance R&D

04.15.14 | By Scott LaGanga

Collaboration was rightly a focal point of #PhRMA14 because it is incredibly important to developing new medicines. As PhRMA CEO John Castellani said at the meeting, the industry is changing rapidly and we continue to compete by “joining hands…building new strength and breadth…[and] adapting and leading.” One of the most important ways to accomplish this is by incorporating the patient into everything we do. 

By inviting patient groups to #PhRMA14, our goal is to help them understand more about the biopharmaceutical industry, increase their awareness of what the sector is doing and ensure their perspectives inform the research and development process. By doing this, we can more efficiently bring the new, innovative treatments to the people who need them most.

At #PhRMA14, I spoke to individuals whose lives had been affected by cancer, diabetes, Alzheimer’s and more, and their insight into how to best treat some of the most devastating diseases is essential to consider as we move forward. As part of our efforts to integrate various perspectives into the meeting, a number of stakeholders shared their thoughts onsite through our Conversations forum. I encourage you to watch the videos where they share their drive toward greater collaboration.

Collaboration and communication, however, cannot only occur during the Annual Meeting, and it is my job to ensure it’s happening year-round. We are constantly listening to and learning from patient groups and other stakeholders about the issues that matter most to them and the populations they serve.

Over the past year, we have made tremendous headway toward increasing our communications efforts through initiatives such as the “I’m In” campaign, which focuses on increasing diversity in clinical trials, and the Partnership to Fight Chronic Disease’s commitment to raising awareness of the tremendous impact chronic disease has on our health care system.

The patient is central to everything we do, and I encourage you to be part of the conversation and share your thoughts on what the biopharmaceutical industry can be doing better through The Catalyst, Facebook and Twitter. I promise that we are listening every day. 


Hide Comments

More On PhRMA — powered by PhRMApedia


Cost in Context